Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.06 billion for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.06B | +2.5% |
| 2024 | $1.04B | +12.4% |
| 2023 | $921.52M | +4.0% |
| 2022 | $886.20M | +8.6% |
| 2021 | $815.85M | +9.5% |
| 2020 | $744.86M | +25.1% |
| 2019 | $595.43M | +31.4% |
| 2018 | $453.02M | +69.4% |
| 2017 | $267.48M | +39.5% |
| 2016 | $191.75M | +117.9% |
| 2015 | $88.01M | +116.2% |
| 2014 | $40.70M | +21.6% |
| 2013 | $33.46M | -41.9% |
| 2012 | $57.57M | +509.7% |
| 2011 | $9.44M | +121.3% |
| 2010 | -$44.32M | -619.9% |
| 2009 | -$6.16M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.05B | +4.2% | -1.3% |
| June 30, 2025 | $1.06B | +11.1% | +3.2% |
| March 31, 2025 | $1.03B | +10.9% | -0.5% |
| December 31, 2024 | $1.04B | +12.4% | +2.8% |
| September 30, 2024 | $1.01B | +10.4% | +5.2% |
| June 30, 2024 | $957.45M | +4.1% | +3.0% |
| March 31, 2024 | $929.17M | +1.9% | +0.8% |
| December 31, 2023 | $921.52M | +4.0% | +1.0% |
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +2.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s stockholders equity has grown by 17346.8% (from -$6.16 million to $1.06 billion).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: